Company Leadership Change - CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition [1] - Dr. Sandra Milligan, the President, will serve as interim CEO while a search for a permanent successor is conducted [1][2] - The Board expressed gratitude for Sandford's contributions, including stabilizing the business and launching the OvaWatch multivariate assay [2] Product Development and Portfolio - Aspira Women’s Health Inc. focuses on the development of noninvasive, AI-powered tests for gynecologic diseases [3] - The OvaSuite portfolio includes OvaWatch and Ova1Plus, which provide comprehensive blood tests for ovarian cancer risk assessment [4] - OvaWatch has a negative predictive value of 99% and is used for women with indeterminate or benign adnexal masses [4] - The company is developing tests to enhance ovarian cancer diagnostics and address endometriosis, aiming to combine microRNA and protein biomarkers with patient data [4]
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO